Consensus KALA BIO, Inc. Deutsche Boerse AG

Equities

27F0

US4831192020

Real-time Estimate Tradegate Other stock markets 11:50:48 01/07/2024 BST			5-day change	1st Jan Change
6.705 ^EUR	+8.32%		+30.50%	-2.04%

06-28	KALA BIO, Inc. announced that it has received $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP	CI
06-27	Top Midday Gainers	MT

Evolution of the average Target Price on KALA BIO, Inc.

Price target over the last 5 years

History of analyst recommendation changes

d99.Yu8jGgYK-9DUD9rA_3tVIbNdDIe5Rp4FbXf50pw5s1U.CaV5LFJ5rZOnTpn3txEhZuVpXeCLdc5UVRaDl6VywWxTrE94aWHNn-N_lw~aac4a0104f94760d63113e683f7c9f68

Analyst Recommendations on KALA BIO, Inc.

HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $18 From $21, Maintains Buy Rating	05-17	MT
HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating	04-02	MT
HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $22 From $24, Maintains Buy Rating	11-17	MT
Wedbush Lowers Kala Pharmaceuticals' PT to $22 From $39, Moves US Launch Estimate for Lead Asset KPI-012; Maintains Outperform Rating	11-14	MT
Wedbush Cuts Kala Pharmaceuticals' Price Target to $39 From $42, Maintains Outperform Rating	04/08/23	MT
HC Wainwright & Co. Adjusts Price Target on Kala Pharmaceuticals to $22 From $20, Keeps Buy Rating	12/04/23	MT
HC Wainwright Adjusts Price Target on Kala Pharmaceuticals to $20 From $12, Keeps Buy Rating	06/03/23	MT
Wedbush Lowers Kala Pharmaceuticals' Price Target to $42 From $47 Due to Increased Share Count, Keeps Outperform Rating	06/03/23	MT
Wedbush Raises Kala Pharmaceuticals' PT to $47 From $3 on Reduced Share Count to Account for Reverse Stock Split; Keeps Outperform Rating	09/11/22	MT
HC Wainwright Adjusts Kala Pharmaceuticals' Price Target to $2.50 From $4, Keeps Buy Rating	15/08/22	MT
Oppenheimer Adjusts Kala Pharmaceuticals' Price Target to $2 From $5, Maintains Outperform Rating	24/05/22	MT
HC Wainwright Adjusts Kala Pharmaceuticals' Price Target to $4 From $5, Keeps Buy Rating	24/05/22	MT
HC Wainwright Trims Kala Pharmaceuticals' Price Target to $5 From $6, Maintains Buy Rating	17/05/22	MT
HC Wainwright Adjusts Price Target on Kala Pharmaceuticals to $5 From $6, Reiterates Buy Rating	17/05/22	MT
Wedbush Adjusts Kala Pharmaceuticals' Price Target to $3 From $6, Keeps Outperform Rating	17/05/22	MT
Northland Capital Adjusts Kala Pharmaceuticals' Price Target to $4 from $6, Keeps Outperform Rating	30/03/22	MT
Oppenheimer Adjusts Kala Pharmaceuticals Price Target to $5 From $8, Maintains Outperform Rating	30/03/22	MT
HC Wainwright Adjusts Kala Pharmaceuticals' Price Target to $6 from $9, Keeps Buy Rating	30/03/22	MT
JPMorgan Downgrades Kala Pharmaceuticals to Underweight From Neutral; Price Target is $1.50	30/03/22	MT
Wedbush Lowers Kala Pharmaceuticals' Price Target to $6 From $16 on 'Persisting Issues' Affecting Inveltys, Eysuvis Launches; Outperform Rating Kept	15/12/21	MT
Wedbush Cuts Kala Pharmaceuticals' Price Target $16 From $43, Citing Inveltys, Eysuvis Penetration Estimates; Outperform Rating Kept	16/11/21	MT
KALA PHARMACEUTICALS : Oppenheimer Adjusts Kala Pharmaceuticals PT to $13 From $15, Maintains Outperform Rating	22/10/21	MT
KALA PHARMACEUTICALS : Oppenheimer Adjusts Kala Pharmaceuticals PT to $15 From $22, Maintains Outperform Rating	06/08/21	MT
KALA PHARMACEUTICALS : HC Wainwright Adjusts Kala Pharmaceuticals' Price Target to $11 From $14, Maintains Buy Rating	06/08/21	MT
KALA PHARMACEUTICALS : JPMorgan Downgrades Kala Pharmaceuticals to Neutral From Overweight	06/08/21	MT